Elliot Ehrich has dedicated his career to translating scientific discoveries into new medicines for illnesses that have no effective treatments or are inadequately addressed by existing therapies. Over the course of 25+ years in pharma and biotech, he has led or directly contributed to the discovery, development, and successful registration of 8 medicines across a spectrum of therapeutic areas.

Elliot joined LifeMine from Skyhawk Therapeutics, where he served as President and led research, drug discovery, and drug development activities. Prior to Skyhawk, Elliot was a Venture Partner at 5AM Ventures, a venture capital firm focused on early- stage life science companies.

Elliot had previously spent 18 years at Alkermes, Inc., where he served as Executive Vice President of Research & Development and Chief Medical Officer. During his tenure, Elliot initiated a transformation of the company’s R&D focus from medicines based on drug delivery technology to a diverse portfolio of novel, proprietary small molecule therapeutics. In doing so, he led the discovery, development, and, ultimately, the FDA registration of a series of medicines for multiple therapeutic indications, including schizophrenia, alcohol and opioid dependence, and multiple sclerosis. He also initiated a novel cytokine program for the treatment of malignancy, which is in ongoing phase 3 clinical development.

Elliot began his industry career in the clinical pharmacology group at Merck Research Labs, where he gained extensive experience in the assessment of human pharmacokinetics and drug-exposure-response relationships. He then spent several years working in pulmonary-immunology clinical development at Merck.

Elliot received a B.A. in Biochemistry from Princeton University. After graduating, he was a predoctoral fellow in molecular genetics at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. He subsequently received an M.D. from Columbia University and completed an internship and residency in internal medicine at Stanford University. After residency, Elliot continued at Stanford and completed a clinical fellowship in immunology and rheumatology followed by a Cancer Research Institute-sponsored postdoctoral fellowship in T cell biology in the laboratory of Professor Mark Davis.